The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

Bortezomib, a drug useful for the treatment of multiple myeloma, reduces kidney damage in animal models of lupus. Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a therapeutic challenge. In particular, long-lived plasma ce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2008-07, Vol.14 (7), p.748-755
Hauptverfasser:	Neubert, Kirsten, Meister, Silke, Moser, Katrin, Weisel, Florian, Maseda, Damian, Amann, Kerstin, Wiethe, Carsten, Winkler, Thomas H, Kalden, Joachim R, Manz, Rudolf A, Voll, Reinhard E
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Autoimmune diseases Biomedical and Life Sciences Biomedicine Biosynthesis Boronic Acids - pharmacology Bortezomib Cancer Research Cellular biology Complications and side effects Deoxyribonucleic acid Development and progression DNA Dosage and administration Drug therapy Health aspects Infectious Diseases Inhibitor drugs Inhibitors Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - enzymology Lupus Erythematosus, Systemic - immunology Medical research Metabolic Diseases Mice Mice, Inbred BALB C Mice, Inbred MRL lpr Mice, Inbred NZB Models, Immunological Molecular Medicine Multiple myeloma Nephritis Nephritis - immunology Nephritis - prevention & control Neurosciences Ovalbumin Physiological aspects Plasma cells Plasma Cells - drug effects Protease Inhibitors - pharmacology Proteasome Inhibitors Pyrazines - pharmacology Rodents Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!